Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma

Clin Nucl Med. 2015 Apr;40(4):309-13. doi: 10.1097/RLU.0000000000000670.

Abstract

Purpose: The differentiation of oncocytoma from renal cell carcinoma (RCC) remains a challenge with currently available cross-sectional imaging techniques. As a result, a large number of patients harboring a benign oncocytoma undergo unnecessary surgical resection. In this study, we explored the utility of 99mTc-MIBI SPECT/CT for the differentiation of these tumors based on the hypothesis that the large number of mitochondria in oncocytomas would lead to increased 99mTc-MIBI uptake.

Patients and methods: In total, 6 patients (3 with oncocytoma and 3 with RCC) were imaged with 99mTc-MIBI SPECT/CT. Relative quantification was performed by measuring tumor-to-normal renal parenchyma background ratios.

Results: All 3 oncocytomas demonstrated radiotracer uptake near or above the normal renal parenchymal uptake (range of uptake ratios, 0.85-1.78). In contrast, the 3 RCCs were profoundly photopenic relative to renal background (range of uptake ratios, 0.21-0.31).

Conclusions: 99mTc-MIBI SPECT/CT appears to be of value in scintigraphically distinguishing benign renal oncocytoma from RCC.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoma, Oxyphilic / diagnostic imaging*
  • Adult
  • Aged
  • Carcinoma, Renal Cell / diagnostic imaging*
  • Diagnosis, Differential
  • Female
  • Humans
  • Kidney Neoplasms / diagnostic imaging*
  • Male
  • Middle Aged
  • Multimodal Imaging*
  • Radiopharmaceuticals
  • Technetium Tc 99m Sestamibi
  • Tomography, Emission-Computed, Single-Photon*
  • Tomography, X-Ray Computed*

Substances

  • Radiopharmaceuticals
  • Technetium Tc 99m Sestamibi

Supplementary concepts

  • Oncocytoma, renal